Zika vaccine: GeoVax reports earnest formula in mice

GeoVax Labs, Inc., a biotechnology association building tellurian vaccines, announces a vital step brazen in the growth of a vaccine claimant for insurance opposite Zika virus (ZIKV). Preliminary contrast in a rarely severe plea indication showed the candidate, GEO-ZM02, supposing 100% insurance to mice putrescent with a fatal sip of ZIKV. The investigate was saved by a extend from the U.S. Centers for Disease Control and Prevention (CDC), which also supposing technical assistance.


During testing, mice were given a single-dose vaccination of GEO-ZM02 into flesh tissue, then putrescent with a fatal sip of ZIKV administered directly to the brain. All vaccinated mice survived since all unvaccinated mice died within a week of infection.

Currently, no vaccine or medicine exists for the impediment or diagnosis of ZIKV infection.

GEO-ZM02 uses GeoVax’s proven MVA vaccine height that has been shown to be protected and to satisfy durable antibody and T-cell responses in mixed tellurian clinical trials for GeoVax’s preventative HIV vaccine. Using the same platform, GeoVax’s Ebola vaccine has been shown to strengthen 100% of rhesus monkeys opposite genocide caused by Ebola virus on a single-dose vaccination.

Farshad Guirakhoo, PhD, GeoVax’s Chief Scientific Officer, stated, “We trust our MVA vaccine height potentially offers the best resolution to safely strengthen at-risk populations from the Zika epidemic. GEO-ZM02 not only has the intensity of a single-dose vaccine, which is unsentimental to fight epidemics in resource-strained countries, but also does not bear the risk of enhancing other flavivirus infections, such as dengue virus, in vaccinated subjects. This phenomenon, called Antibody Dependent Enhancement (ADE) of infection, has been the subject of new publications, and is a reserve regard for other Zika vaccines underneath growth that implement the constructional Envelope (E) protein of ZIKV for their vaccine construct. Our vaccine is formed on the non-structural-1 (NS1) protein of ZIKV, which is not concerned in ADE. Moreover, the NS1 protein is extravagantly secreted into the blood of a ZIKV-infected particular and plays a vicious purpose in flavivirus merger by mosquitoes by overcoming the defence separator of the butterfly midgut. Therefore, GEO-ZM02 should not only strengthen populations opposite ZIKV infections but could also retard serve delivery of ZIKV from humans back to the butterfly host.”

Robert McNally, PhD, GeoVax’s President and Chief Executive Officer, commented, “The results from this investigate are considerable and give us certainty in dire brazen with our Zika vaccine module and enchanting with intensity partners for clinical trials and commercialization. With the correct resources, we expect that tellurian clinical trials could embark within 18 months.”

Article source: http://outbreaknewstoday.com/zika-vaccine-geovax-reports-promising-results-mice-15629/

Read previous post:
Donated spermatazoa in Florida counties might be putrescent with Zika

The US Centers for Disease Control (CDC) has identified a potential risk of Zika virus transmission from donor sperm in the...